Trial Profile
Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Nov 2019
Price :
$35
*
At a glance
- Drugs H 1PV (Primary) ; H 1PV (Primary) ; H 1PV (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Oryx GmbH & Co
- 04 Nov 2019 According to an Oryx GmbH & Co media release, the company received a positive feedback and endorsement from both agencies to evaluate its proposed plans for pivotal studies.
- 04 Nov 2019 According to an Oryx GmbH & Co media release, based on the data from this trial and the follow-up program the company requested meetings with the regulatory authorities both in the EU and US to discuss pivotal studies with ParvOryx in combination with bevacizumab for the treatment of recurrent glioblastoma multiforme (rGBM).
- 16 May 2018 Results presented in the GmbH & Co media release.